Rhythm Pharmaceuticals, Inc. (RYTM) — 10-Q Filings

10-Q Filings (6)

• Rhythm Pharma's Revenue Soars 54% Amid Widening Losses — Nov 4, 2025 Risk: medium
  Rhythm Pharmaceuticals, Inc. (RYTM) reported a significant increase in product revenue, reaching $51.298 million for the three months ended September 30, 2025,
• Rhythm Pharma Narrows Q2 Loss Amidst Strategic Equity Raises — Aug 5, 2025 Risk: high
  RHYTHM PHARMACEUTICALS, INC. reported a net loss of $62.39 million for the three months ended June 30, 2025, compared to a net loss of $63.91 million for the sa
• Rhythm Pharma Files Q1 2025 10-Q, Reports $623.9M Assets — May 7, 2025 Risk: medium
  Rhythm Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $623.9 million and total liabilities of $
• Rhythm Pharma Q3 2024: Assets $594.3M, Liabilities $61.4M — Nov 6, 2024 Risk: medium
  Rhythm Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $594.3 million and total liabilities
• Rhythm Pharma Q2 2024: Assets $594.3M, Liabilities $61.1M — Aug 6, 2024 Risk: medium
  Rhythm Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $594.3 million and total liabilities of $6
• Rhythm Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  RHYTHM PHARMACEUTICALS, INC. (RYTM) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Rhythm Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX